REPL - What's Going On With Cancer-Focused Replimune Stock Today? | Benzinga
Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC).
The CERPASS study did not meet either of the two primary endpoints of complete response rate (CRR) or overall response rate (ORR).
RP1, in combination with cemiplimab, increased the CRR versus cemiplimab alone (38.1% vs. 25%, p=0.040), which was just short of the required threshold for statistical significance in this study (p<0.025).
Among the 83 ...